Journal article
Targeting apoptosis: preclinical and early clinical experience with mapatumumab, an agonist monoclonal antibody targeting TRAIL-R1
Abstract
In spite of the advances in survival with chemotherapy and radiotherapy, many cancer patients continue to experience failure with treatments. Advances in molecular oncology and the development of numerous targeted therapies, used by themselves or in combination with at present available treatments such as chemotherapy and radiation, will hopefully improve the fate of these patients. It has been well understood for many years now that …
Authors
Moretto P; Hotte SJ
Journal
Expert Opinion on Investigational Drugs, Vol. 18, No. 3, pp. 311–325
Publisher
Taylor & Francis
Publication Date
3 2009
DOI
10.1517/13543780902752463
ISSN
1354-3784